Informations et données sanitaires pour l’action: Cameroun

Au Cameroun, le DHIS2 centralise les données de santé de près de 6 000 formations sanitaires, avec une remontée mensuelle des données des FOSA vers les niveaux district, régional et national. La présentation identifie cinq lacunes clés du système d’information : intégration limitée des registres scolaires dans la microplanification, absence de désagrégation par cohorte d’âge […]

Défis et bonnes pratiques pour maintenir la prestation après l’introduction du MAC: l’expérience du Nigéria dans l’élimination du cancer du col de l’utérus

Au Nigéria, la vaccination contre le HPV a été introduite en deux phases — Phase 1 ciblant 16 États (2023) et Phase 2 couvrant 21 États supplémentaires (octobre 2024) — avec une routinisation immédiate après chaque campagne de cohortes multi-âges (MAC). La combinaison des campagnes et de la vaccination de routine a permis d’atteindre environ […]

Efficacy Of Quadrivalent Human Papillomavirus Vaccine Among Kenyan Adolescents And Young Adults Living With HIV Nine Years After Initial Vaccination

In Kenya, a nine-year follow-up of a cohort of 180 adolescents living with HIV who received three doses of the quadrivalent HPV vaccine at ages 9–14 found sustained vaccine-specific protection, with zero persistent infections detected for HPV types 11, 16, or 18 among 151 evaluable participants. Only two participants (1.3%) had any vaccine-genotype persistent infection, […]

Overcoming Barriers To Human Papillomavirus Vaccine Uptake In Sierra Leone: Insights From Formative Research In Four Low-Performing Districts

In Sierra Leone, HPV vaccination coverage fell sharply from over 100% in 2022 to 31.3% in 2023, prompting CHAI and the Ministry of Health EPI programme to conduct formative research across the four lowest-performing districts — Bonthe, Koinadugu, Kenema, and Western Area Rural. A mixed-methods study combining facility data audits and semi-structured interviews with healthcare […]

Using Geographic information System mapping for Evidence-Based Planning to Reach HPV vaccine Target Girls and Zero-Dose Children: Experience from Jigjiga Town, Ethiopia.

In Ethiopia, a 20-day house-to-house GIS mapping exercise conducted in Jigjiga town (Somali region) between August and September 2024 revealed major discrepancies between projected and actual target populations: official estimates placed the HPV-eligible girl population at 6,770, while the headcount identified 11,300 — a 67% undercount — and 14,935 girls were ultimately vaccinated, representing 132% […]

Using Routine Human Papillomavirus Vaccination Data to Guide High-Impact Community Outreach in Nigeria

In Nigeria, routine HPV vaccination coverage among nine-year-old girls remains low in Kano State, constrained by limited awareness, persistent myths, and geographic and economic barriers. Pathfinder International used DHIS2 data to identify low-coverage local government areas and implemented targeted community outreach in collaboration with State Primary Health Care Development Boards, deploying trained vaccination teams alongside […]

Health Information Systems and Data for Action: Q&A Session

In this Q&A following country presentations on health information systems, participants raised questions around four cross-cutting themes: reaching out-of-school girls, tracking HIV-positive adolescents requiring three HPV doses, managing data collection in low-connectivity rural areas, and the timeline and resources involved in transitioning from paper-based to digital systems. Cameroon’s representative described how opposition from Catholic churches […]

Financial and/or sustainability in the context of expanding target population for vaccination – Q&A

Discussion addressed the differentiated pricing landscape for HPV vaccines, clarifying that GAVI-eligible countries may access GAVI prices even for expanded target groups and that UNICEF procurement functions as an indirect pool procurement mechanism benefiting countries with small purchasing volumes. On the economics of local manufacturing, Bloem acknowledged the 10-year timeline and higher per-dose costs typical […]

>